Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

NCT02109341 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
148
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica